{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-072821","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2024-06-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.036118+00:00","generated_at":"2026-06-01T03:51:08.999404+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Cara Therapeutics cuts workforce 70% after discontinuing NP program, explores strategic alternatives","bullets":["Board approved streamlined operating plan and strategic alternatives after discontinuing NP program following KOURAGE-1 Part A results on June 12, 2024.","Workforce reduction of approximately 70%, substantially complete by June 30, 2024.","Expects approximately $2.6M in total charges for termination benefits, recognized in Q2 and Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-072821","json":"https://secwatch.observer/filing/0001104659-24-072821.json","markdown":"https://secwatch.observer/filing/0001104659-24-072821.md","text":"https://secwatch.observer/filing/0001104659-24-072821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465924072821/0001104659-24-072821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465924072821/tm2417536d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:51:08.999404+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}